<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257074</url>
  </required_header>
  <id_info>
    <org_study_id>PENEMS1010</org_study_id>
    <nct_id>NCT01257074</nct_id>
  </id_info>
  <brief_title>Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis</brief_title>
  <official_title>A Randomized, Double-Blind, to Compare Non-inferiority Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Herpes labialis is the most common recurrent manifestation of herpes simplex. The purpose of
      this study is to check the non-inferiority efficacy and safety of penciclovir 10mg/g as
      treatment for Herpes Labialis in comparison to acyclovir 50mg/g.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      • Double blinded non-inferiority prospective parallel-group, intend to treat trial.

      Study design:

        -  Experiment duration: 10 days

        -  3 visits (days 1,5 and 10)

        -  Erythema, papule, vesicle, ulcer, crust and healed skin evaluation

        -  Adverse events evaluation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy will be evaluated by the proportion of subjects with non herpes labialis manifestation</measure>
    <time_frame>Day 10</time_frame>
    <description>Symptoms evaluated: erythema, papule, vesicle, ulcer, crust, or healed skin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Herpes Labialis</condition>
  <arm_group>
    <arm_group_label>Drug 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Penciclovir 10mg/g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyclovir 50mg/g</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir 50mg/g</intervention_name>
    <description>Cream, dose 5 times daily during 5 days</description>
    <arm_group_label>Drug 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penciclovir 10mg/g</intervention_name>
    <description>Cream, dose 5 times daily during 5 days</description>
    <arm_group_label>Drug 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able to understand the study procedures agree to participate and give
             written consent.

          2. Patients with clinical diagnosis of recurrent herpes labialis and are in the prodromal
             period (stinging, itching, burning and erythema) at the onset of signs / symptoms in
             the last 12-24 hours;

          3. No history of reaction to topical products;

        Exclusion Criteria:

          1. Pregnancy or risk of pregnancy.

          2. Lactation

          3. Use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study.)

          4. Sunlight over exposure in the last 15 days.

          5. Any pathology or past medical condition that can interfere with this protocol.

          6. AINH use, hormonal anti-inflammatory, analgesic and immunosuppressive drugs (in the
             last 30 days and during the study);

          7. Patients with immunodeficiency and/or immunosuppressive disease;

          8. Sunlight exposure in the last 15 days;

          9. Hypersensitivity to components of the formula;

         10. Other conditions deemed reasonable by the medical investigator as to the
             disqualification of the individual from study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavia Addor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medcin Instituto da Pele Ltda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Flavia Addor</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes Simplex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Labialis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Penciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

